CenterBook Partners LP reduced its stake in shares of ASP Isotopes Inc. (NASDAQ:ASPI - Free Report) by 88.3% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 175,959 shares of the company's stock after selling 1,325,085 shares during the quarter. CenterBook Partners LP owned about 0.23% of ASP Isotopes worth $825,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other institutional investors have also added to or reduced their stakes in ASPI. LPL Financial LLC purchased a new stake in ASP Isotopes during the 4th quarter valued at approximately $54,000. JPMorgan Chase & Co. grew its holdings in ASP Isotopes by 854.6% during the 4th quarter. JPMorgan Chase & Co. now owns 211,893 shares of the company's stock valued at $960,000 after buying an additional 189,697 shares in the last quarter. Geode Capital Management LLC grew its holdings in ASP Isotopes by 5.1% during the 4th quarter. Geode Capital Management LLC now owns 1,175,450 shares of the company's stock valued at $5,326,000 after buying an additional 57,027 shares in the last quarter. Wells Fargo & Company MN grew its holdings in ASP Isotopes by 57.4% during the 4th quarter. Wells Fargo & Company MN now owns 24,472 shares of the company's stock valued at $111,000 after buying an additional 8,925 shares in the last quarter. Finally, Russell Investments Group Ltd. grew its holdings in ASP Isotopes by 56.3% during the 4th quarter. Russell Investments Group Ltd. now owns 10,221 shares of the company's stock valued at $46,000 after buying an additional 3,682 shares in the last quarter. 16.80% of the stock is owned by hedge funds and other institutional investors.
ASP Isotopes Price Performance
Shares of NASDAQ ASPI traded up $0.42 during midday trading on Tuesday, reaching $10.34. 3,958,207 shares of the stock traded hands, compared to its average volume of 2,972,040. The company has a debt-to-equity ratio of 0.80, a current ratio of 7.21 and a quick ratio of 7.17. The stock has a market capitalization of $867.86 million, a PE ratio of -16.87 and a beta of 3.36. ASP Isotopes Inc. has a one year low of $1.95 and a one year high of $10.82. The company's 50 day moving average is $8.48 and its 200 day moving average is $6.52.
Analyst Ratings Changes
Separately, Canaccord Genuity Group increased their price objective on shares of ASP Isotopes from $8.50 to $11.00 and gave the company a "buy" rating in a report on Wednesday, May 21st.
Get Our Latest Research Report on ASPI
ASP Isotopes Company Profile
(
Free Report)
ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235.
Recommended Stories

Before you consider ASP Isotopes, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ASP Isotopes wasn't on the list.
While ASP Isotopes currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.